Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.32 |
| ▸ | PTPRF | P10586 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743037 | 0.87 | PPARA (0.35) | PPARGPPARASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6744721 | 0.84 | PPARA (0.40) | PPARGPPARALTA4HHDAC8 | |
| SCHEMBL6361340 | 0.77 | LTA4H (0.37) | PPARGPPARALTA4HHDAC8 | |
| SCHEMBL6746587 | 0.76 | EPHX2 (0.34) | EPHX2LTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6745446 | 0.75 | PPARA (0.36) | PPARGPPARAHDAC1HDAC6 | |
| SCHEMBL6744680 | 0.75 | HDAC8 (0.36) | EPHX2LTA4HHDAC1HDAC6HDAC8 | |
| SCHEMBL6743967 | 0.73 | HDAC2 (0.33) | PPARGPPARAEPHX2LTA4HHDAC1 | |
| SCHEMBL6750127 | 0.70 | PPARG (0.42) | PPARGPPARALTA4HHDAC1HDAC6 | |
| SCHEMBL6746546 | 0.70 | LTA4H (0.44) | PPARGPPARALTA4HHDAC1HDAC6 | |
| SCHEMBL6744422 | 0.70 | LTA4H (0.36) | PPARGPPARALTA4HHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885EPHX2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.